{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:16:10Z","timestamp":1792404970444,"version":"4.4.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clml.2022.07.008","type":"journal-article","created":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T09:20:47Z","timestamp":1658049647000},"page":"805-811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hodgkin Lymphoma on Hemodialysis: A Review of Treatment and Recommendations"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2896-7737","authenticated-orcid":false,"given":"Hajime","family":"Yasuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.07.008_bib0001","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1080\/10428194.2020.1797012","article-title":"Clinical and prognostic role of interim 18F-FDG PET\/CT in elderly Hodgkin lymphoma: a dual-center experience","volume":"61","author":"Albano","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.07.008_bib0002","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1159\/000520028","article-title":"Medication burden and prescribing patterns in patients on hemodialysis in the USA, 2013-2017","volume":"52","author":"Paik","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.clml.2022.07.008_bib0003","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/clpt.2009.150","article-title":"Challenges in developing evidence-based drug dosing guidelines for adults and children receiving renal replacement therapy","volume":"86","author":"Mueller","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clml.2022.07.008_bib0004","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/17512433.2017.1323632","article-title":"Guidance to develop individual dose recommendations for patients on chronic hemodialysis","volume":"10","author":"Gotta","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.clml.2022.07.008_bib0005","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/ajh.25856","article-title":"Hodgkin lymphoma: a 2020 update on diagnosis, risk-stratification, and management","volume":"95","author":"Ansell","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.07.008_bib0006","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1111\/cas.14933","article-title":"Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review","volume":"112","author":"Yasuda","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2022.07.008_bib0007","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1200\/JCO.2004.03.147","article-title":"Unusual sites of Hodgkin's lymphoma: CASE 3. Cholemic nephrosis in Hodgkin's lymphoma with liver involvement","volume":"22","author":"Kiewe","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.008_bib0008","first-page":"41","article-title":"Renal infiltration presenting as acute kidney injury in Hodgkin lymphoma - a case report and review of the literature","volume":"10","author":"Silva","year":"2018","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.clml.2022.07.008_bib0009","first-page":"169","article-title":"Distribution and excretion of adriamycin in man","volume":"19","author":"Di Fronzo","year":"1973","journal-title":"Biomedicine"},{"key":"10.1016\/j.clml.2022.07.008_bib0010","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/annonc\/mdp598","article-title":"Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients","volume":"21","author":"Janus","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.07.008_bib0011","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1634\/theoncologist.12-9-1070","article-title":"Commentary: Oncologic drugs in patients with organ dysfunction: a summary","volume":"12","author":"Superfin","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2022.07.008_bib0012","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mpo.2950120503","article-title":"Bleomycin pulmonary toxicity: its relationship to renal dysfunction","volume":"12","author":"Dalgleish","year":"1984","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.clml.2022.07.008_bib0013","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.07.008_bib0014","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2165\/00003088-198815050-00005","article-title":"Guide to drug dosage in renal failure","volume":"15","author":"Bennett","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clml.2022.07.008_bib0015","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/ijgc-00009577-200707000-00001","article-title":"Systemic anticancer therapy in gynecological cancer patients with renal dysfunction","volume":"17","author":"Li","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.clml.2022.07.008_bib0016","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/BF00685719","article-title":"Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency","volume":"27","author":"Motzer","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2022.07.008_bib0017","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/j.1442-2042.2008.02123.x","article-title":"Pharmacokinetics of cisplatin and methotrexate after M-VAC chemotherapy for advanced urothelial cancer in hemodialysis patients","volume":"15","author":"Matsumoto","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.clml.2022.07.008_bib0018","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/bs.podrm.2015.12.002","article-title":"Dacarbazine","volume":"41","author":"Al-Badr","year":"2016","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"10.1016\/j.clml.2022.07.008_bib0019","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5227\/skincancer.20.93","article-title":"DAC-Tam therapy as a treatment of the progressive stage of melanoma in a patient on maintenance hemodialysis","volume":"20","author":"Inozume","year":"2005","journal-title":"Skin Cancer"},{"key":"10.1016\/j.clml.2022.07.008_bib0020","first-page":"1709","article-title":"A case of liver metastasis from anorectal malignant melanoma on hemodialysis treated by chemotherapy","volume":"34","author":"Tezuka","year":"2007","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.clml.2022.07.008_bib0021","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.008_bib0022","first-page":"2566","article-title":"Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function","volume":"46","author":"D'Incalci","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2022.07.008_bib0023","first-page":"379","article-title":"Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients","volume":"44","author":"Hande","year":"1984","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2022.07.008_bib0024","first-page":"1279","article-title":"Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient","volume":"69","author":"Holthuis","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clml.2022.07.008_bib0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/sj.bjc.6600687","article-title":"Feasibility of combination chemotherapy with cisplatin and etoposide for hemodialysis patients with lung cancer","volume":"88","author":"Watanabe","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2022.07.008_bib0026","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/annonc\/mdh008","article-title":"Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis","volume":"15","author":"Inoue","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.07.008_bib0027","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"44","author":"de Jonge","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clml.2022.07.008_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000167","article-title":"Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Societa Italiana di Nefrologia (SIN)","volume":"2","author":"Pedrazzoli","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.clml.2022.07.008_bib0029","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3109\/10428194.2015.1115033","article-title":"Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis","volume":"57","author":"Ochi","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.07.008_bib0030","first-page":"1362","article-title":"Cadaveric renal transplantation in two patients with preexisting Hodgkin's lymphoma","volume":"16","author":"Stock","year":"1984","journal-title":"Transplant Proc"},{"key":"10.1016\/j.clml.2022.07.008_bib0031","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/ndt\/16.8.1722","article-title":"Lymphomas and IgA nephropathy","volume":"16","author":"Cherubini","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clml.2022.07.008_bib0032","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2050-7771-2-12","article-title":"CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function","volume":"2","author":"Thakar","year":"2014","journal-title":"Biomark Res"},{"key":"10.1016\/j.clml.2022.07.008_bib0033","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/bcp.12988","article-title":"Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies and hepatic or renal impairment","volume":"82","author":"Zhao","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clml.2022.07.008_bib0034","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1016\/j.clml.2019.07.443","article-title":"Successful employment of brentuximab vedotin in a patient undergoing hemodialysis: The first real-life experience","volume":"19","author":"Nanni","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.07.008_bib0035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000523823","article-title":"Hodgkin lymphoma on hemodialysis successfully treated with extended courses of brentuximab vedotin","volume":"15","author":"Uchimura","year":"2022","journal-title":"Case Reports in Oncol"},{"key":"10.1016\/j.clml.2022.07.008_bib0036","doi-asserted-by":"crossref","first-page":"399","DOI":"10.34067\/KID.0000422020","article-title":"Use of immune checkpoint inhibitors in end stage kidney disease patients, single center experience and review of the literature","volume":"1","author":"Hirsch","year":"2020","journal-title":"Kidney360"},{"key":"10.1016\/j.clml.2022.07.008_bib0037","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/ckj\/sfab090","article-title":"Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review","volume":"14","author":"Kitchlu","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.clml.2022.07.008_bib0038","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1111\/1759-7714.13197","article-title":"Monitoring antibody binding to T cells in a pembrolizumab-treated patient with lung adenocarcinoma on hemodialysis","volume":"10","author":"Osa","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.clml.2022.07.008_bib0039","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clml.2022.07.008_bib0040","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10637-018-0673-y","article-title":"Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review","volume":"37","author":"Cheun","year":"2019","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2022.07.008_bib0041","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.10213","article-title":"Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis","volume":"71","author":"Jillella","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.07.008_bib0042","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood.V76.7.1293.1293","article-title":"CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma","volume":"76","author":"Chao","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.008_bib0043","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3747\/pdi.2015.00119","article-title":"Hodgkin's lymphoma diagnosed from peritoneal effluent","volume":"36","author":"Viray","year":"2016","journal-title":"Peritoneal Dialysis Internat: J Internat Soc for Peritoneal Dialysis"},{"key":"10.1016\/j.clml.2022.07.008_bib0044","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.008_bib0045","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00280-003-0574-3","article-title":"Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment","volume":"51","author":"Kiani","year":"2003","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:34Z","timestamp":1761871234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022002269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2152265022002269"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hodgkin Lymphoma on Hemodialysis: A Review of Treatment and Recommendations","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}